TheraRadar
← Back
Data updated: Nov 8, 2026

INVENTIA

Generics

INVENTIA is a generic drug manufacturer focused on Infectious Disease, Cardiovascular.

2015
Since
4
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

INVENTIA's Key Drugs

INVENTIA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

INVENTIA's Recent FDA Approvals

INVENTIA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

INVENTIA's Therapeutic Areas

INVENTIA's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
1 drugs
Cardiovascular 50%
1 drugs

INVENTIA's Top Competitors

INVENTIA's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

INVENTIA Pipeline Snapshot

Active clinical trials for INVENTIA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling